Public R&D Policy: The Right Turns of the Wrong Screw? The Case of the German Biotechnology Industry
Authors:
Preprint
- 1 October 2005
- preprint
- Published by Elsevier in SSRN Electronic Journal
Abstract
The German biotechnology industry missed the accession of this key technology in the 1980s. Policy makers make different efforts to overcome shortcomings and recent gaps. Public funding schemes have been implemented to establish a flourish biotech industry in Germany. We assume that R&D policy was driven blind by the idea to catch up with world's biotech leaders and analyse if Germany's R&D policy lost its origins. We do examine, if Germany sacrifice economic funding principles, in particular not discriminating different kinds of "risk" in the field of biotechnology. The study combines survey data of German biotech companies and public R&D funding data on the firm level. The results shed light on the factors which determine public R&D funding and firm's probability of being funded.Keywords
This publication has 25 references indexed in Scilit:
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Publicly Funded R&D Collaborations and Patent Outcome in GermanySSRN Electronic Journal, 2003
- Is public R&D a complement or substitute for private R&D? A review of the econometric evidenceResearch Policy, 2000
- The contrasting roles of government in the development of biotechnology industry in the US and GermanyResearch Policy, 2000
- The Exploration of Technological Diversity and Geographic Localization in Innovation: Start-Up Firms in the Semiconductor IndustrySmall Business Economics, 1997
- The Economics of Small Firms1990
- Innovation and Learning: The Two Faces of R & DThe Economic Journal, 1989
- Who Does R&D and Who Patents?1982
- Success among high-technology firmsBusiness Horizons, 1977
- Economic Welfare and the Allocation of Resources for Invention1962